Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816448 | 0.77 | PLAU (0.53) | NCOA3 | |
| SCHEMBL12443279 | 0.77 | ATM (0.57) | ATMMETTL3 | |
| SCHEMBL8564181 | 0.76 | CASP3 (0.49) | NCOA3 | |
| SCHEMBL4380049 | 0.75 | ATM (0.51) | ATMMETTL3CYP1A2CTSL | |
| SCHEMBL17327757 | 0.73 | TP53 (0.58) | ATMMETTL3CTSKCYP1A2 | |
| SCHEMBL28199380 | 0.72 | ATM (0.48) | ATMMETTL3CYP1A2CTSL | |
| SCHEMBL941093 | 0.72 | TOP2A (0.70) | ATMMETTL3CTSK | |
| SCHEMBL941092 | 0.72 | TOP2A (0.70) | ATMMETTL3CTSK | |
| SCHEMBL9319994 | 0.72 | TOP2A (0.70) | ATMMETTL3CTSK | |
| SCHEMBL28494134 | 0.71 | TOP2A (0.68) | ATMMETTL3CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | claimed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | claimed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | claimed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-8932617-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | ELFORD HOWARD L (US) | 2012-12-27 | — | — | US | disclosed |
| US-8029815-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L | 2011-10-04 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | ELFORD HOWARD L | 2008-02-28 | — | — | US | disclosed |
| EP-1744761-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | Molecules for Health, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005115405-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | MOLECULES FOR HEALTH, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6248782-B1 | ADMINISTERING ENZYME INHIBITOR | ELFORD HOWARD L (US) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | NCOA3 2005/4885ATM 3194/4885METTL3 1513/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | NCOA3 2005/4885ATM 3194/4885METTL3 1513/4885 |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | NCOA3 3044/4885ATM 3292/4885METTL3 3315/4885 |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | NCOA3 3044/4885ATM 3292/4885METTL3 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.